Mitogen-activated protein kinase kinase 3 (MKK3) is a dual threonine/tyrosine protein kinase that regulates inflammation, proliferation and apoptosis through specific phosphorylation and activation of the p38 mitogen-activated protein kinase. However, the role of MKK3 beyond p38-signaling remains elusive. Recently, we reported a protein-protein interaction (PPI) network of cancer-associated genes, termed OncoPPi, as a resource for the scientific community to generate new biological models. Analysis of the OncoPPi connectivity identified MKK3 as one of the major hub proteins in the network. Here, we show that MKK3 interacts with a large number of proteins critical for cell growth and metabolism, including the major oncogenic driver MYC. Multiple complementary approaches were used to demonstrate the direct interaction of MKK3 with MYC in vitro and in vivo. Computational modeling and experimental studies mapped the interaction interface to the MYC helix-loop-helix domain and a novel 15-residue MYC-binding motif in MKK3 (MBM). The MBM in MKK3 is distinct from the known binding sites for p38 or upstream kinases. Functionally, MKK3 stabilized MYC protein, enhanced its transcriptional activity and increased expression of MYC-regulated genes. The defined MBM peptide mimicked the MKK3 effect in promoting MYC activity. Together, the exploration of OncoPPi led to a new biological model in which MKK3 operates by two distinct mechanisms in cellular regulation through its phosphorylation of p38 and its activation of MYC through PPI.
INTRODUCTION
Recent advances in high-throughput technologies and cancer genomics have led to comprehensive profiling of the cancer genome and identification of genes frequently altered in cancer patients. [1] [2] [3] To systematically reveal protein-protein interactions (PPIs) among cancer-associated proteins, we initiated a binary PPI high-throughput screening effort in lung cancer cells. 4 The highthroughput screening-based studies have led to a data set with a network of cancer-associated PPIs (OncoPPi), which are available through the Dashboard and DataPortal of the Cancer Target Discovery and Development (CTD 2 ) Network at the National Cancer Institute. 5 One of the major hubs discovered in OncoPPi is the mitogenactivated protein kinase kinase 3 (MAP2K3, MKK3). MKK3 is a mitogenic, stress-activated and dual-specificity protein kinase known to specifically phosphorylate and activate the p38 mitogen-activated protein kinase leading to cytokine and chemokine release. 6, 7 The p38 pathway is known for its critical role in inflammation and is involved in regulation of the cell cycle and apoptosis. 6 However, the identification of MKK3 as a major hub protein of OncoPPi was notable because of limited knowledge of its function beyond the regulation of the p38-mediated signaling pathway. Among the MKK3-associated proteins, MYC represents a major oncogene driver, offering an opportunity to define new mechanisms of MKK3 function.
Here, we report a new biological model for MKK3 as a novel regulator of the MYC oncogene. This study illustrates an application of OncoPPi as a resource for the community to generate novel biological models based on the newly detected physical interactions between cancer-associated proteins.
RESULTS

MKK3 interacts with diverse cellular signaling proteins
Analysis of the OncoPPi network revealed that MKK3, but not its close homolog MKK6, interacts with multiple proteins from various signaling pathways in addition to its known activator, ASK1, and substrate, p38 (Figure 1a, Supplementary Figure S1A ). 4 To confirm these interactions, we selected ten positive MKK3 PPIs for examination by time-resolved fluorescence resonance energy transfer (TR-FRET) titration assay ( Figure 1b ) and an alternative glutathione S-transferase (GST) affinity resin-based pull down assay (Figures 1c and d) . Indeed, both the TR-FRET assay and the GST-pull down assay supported the interaction of MKK3 with these new partners. These MKK3-binding proteins include the Ser/ Thr kinase 11; cyclin-dependent kinase 4 (CDK4); aurora kinase A; the autophagy regulator, Beclin 1; the angiogenesis modulator hypoxia-inducible factor 1-beta; several membrane-associated growth factor receptors including Ephrin type-A receptor 2, fibroblast growth factor receptor 4 and platelet-derived growth factor receptor alpha ( Figure 1d ); Hippo signaling regulatory protein RASSF1 and the c-MYC (MYC) oncoprotein.
To assess a potential functional connection between MKK3 and its demonstrated binding partners, we examined cancer genomics data (http://cancergenome.nih.gov) and performed mutual exclusivity (ME) analysis 8 with data sets from 11 tumor types ( Supplementary Table S1 , Supplementary Figure S2 ). Consistent with established pathway connectivity, ME analysis showed a strong tendency toward ME for MKK3 and its known substrate p38 (mitogen-activated protein kinase-14) in all tumor types studied ( Supplementary Table S1 ). Similarly, MKK3 alterations showed a tendency toward ME with amplifications of fibroblast growth factor receptor 4, Ephrin type-A receptor 2, platelet-derived growth factor receptor alpha, CDK4 and aurora kinase A, as well as mutations or deletions of Ser/Thr kinase 11 and RASSF1. Alterations in the hypoxia-inducible factor 1-beta coding gene ARNT tend to be mutually exclusive with MKK3 in breast invasive carcinoma (BRCA) and head and neck squamous cell carcinoma. In addition, MKK3 alterations tend to be mutually exclusive with alterations of Beclin 1 in head and neck squamous cell carcinoma, as well as in lung adenocarcinoma, prostate adenocarcinoma, liver hepatocellular carcinoma and sarcoma ( Supplementary Table S1 , Supplementary Figure S2 ). Interestingly, ME analysis also revealed the ME of MKK3 alterations with amplification of the MYC oncogene in the majority of the analyzed tumor types (Supplementary Figure S2 ). These genomics data support the functional association of MKK3 with the newly identified interacting proteins, and suggest that MKK3 may have a role in pathways beyond p38. To test this notion, we further examined the physical interaction and functional consequence of the MKK3 interaction with the oncogenic transcription factor MYC.
MKK3 is associated with MYC in cells
To validate the interaction of MKK3 with MYC, a set of PPI detection methods were utilized in addition to the TR-FRET assay. MKK3 was found in complex with MYC in HEK293T cells following GST-pull down with either GST-MKK3 or GST-MYC ( Figure 2a ). In agreement with the OncoPPi network, we did not detect the interaction between MYC and MKK6 (Supplementary Figures S1B and C). These results support a high-confidence level for OncoPPi PPIs, and suggest distinct biological functions of MKK3 and MKK6 in the regulation of MYC-driven tumorigenesis. To examine whether the MKK3-MYC interaction occurs under physiological conditions, reciprocal co-immunoprecipitation (co-IP) experiments were performed. Indeed, endogenous MKK3 protein was detected in the MYC protein complex in both H1299 lung cancer cells and MCF7 breast cancer cells (Figures 2b-d) . These results support the physical association of MKK3/MYC in cancer cells.
A Venus-based protein fragment complementation assay (PCA), also known as bimolecular fluorescence complementation assay 9 was used to monitor subcellular localization of MKK3 when associated with MYC in live cells. The association of two binding partners to the complementary N-terminal and C-terminal fragment of Venus is expected to reconstitute the Venus protein, leading to increased fluorescence intensity ( Figure 2f ). Consistent with previous reports, MKK3 and p38 expressed as Venus fusions in HeLa cells were observed mostly in the cytoplasm, whereas MYC was in the nucleus ( Figure 2g ). 10, 11 As expected, the green fluorescence PCA signal for the MKK3/p38 interaction was observed primarily in the cytoplasm (Figure 2g ). In contrast, the MKK3/MYC PPI was predominantly localized in the nuclei as shown by overlap of the fluorescent PCA signal with the Hoechststained nuclei ( Figure 2g ). Thus, MKK3 appears to form a protein complex with MYC mostly in the nuclear compartment.
In order to bind DNA, MYC forms a high-affinity complex with its major binding partner MAX. 12 To test if MKK3 also binds to MAX, we performed a TR-FRET assay with the HEK293T cells coexpressing Venus-MKK3/GST-MAX and Venus-MKK3/GST-MYC pairs. In contrast to the MKK3/MYC PPI, we did not observe the interaction between MKK3 and MAX under the same experimental conditions ( Figure 2h ). These data further support a specific association of MKK3 with MYC.
MYC helix-loop-helix domain mediates interaction with MKK3
MYC is a master regulator of gene expression that governs a wide range of cellular functions. 13 Therefore, its activity is tightly regulated. Such regulatory mechanisms are mediated through a number of defined structural domains in MYC, which couple MYC to MYC-recognition sequences in target DNA, to upstream signaling cascades and to cellular protein degradation machinery. 14 of MYC responsible for MKK3 binding, we examined the interaction of MYC MBD-containing fragments with full-length MKK3 in TR-FRET and GST-pull down assays ( Figure 3a ). As shown in Figure 3b , the C-terminal 186-439 fragment containing MBIII and bHLH-LZ of MYC was found in complex with GST-MKK3. Considering the significantly decreased binding observed with the 130-338 fragment containing MBIIIa, MBIIIb and MBIV, these results suggest that the 338-439 binding fragment in the bHLH-LZ region of MYC ( Figure 3a ) may serve as the dominant MKK3binding site. We confirmed this result by using purified GST-MKK3 and His-MYC bHLH-LZ region proteins in a TR-FRET assay. A recombinant GST protein was used as a negative control. The TR-FRET signal for His-MYC bHLH-LZ with GST-MKK3 was fourfold higher than the signal for the MYC/GST control ( Figure 3c ). Then, to assess the affinity of MYC bHLH-LZ to MKK3, the recombinant proteins were subjected to the Bio-Layer interferometry (BLI) assay. 15 BLI is a label-free optical biosensor that measures molecular interactions. For this assay, the His-tagged MYC bHLH-LZ protein bound to the Ni-NTA biosensor was titrated against various concentrations of GST-MKK3 (0-300 nM) to generate the BLI signals, resulting in a dissociation constant of 0.225 ± 0.005 μM ( Figure 3d ). This Kd value is comparable to previously reported affinities for various MAP kinases 16, 17 and for the MYC/MAX interaction (0.167 ± 0.003 μM). 18 Together, these results indicate that the MYC C-terminal bHLH-LZ domain is the primary interaction site for MKK3.
MKK3 121-135 is a novel interaction domain A computational molecular modeling approach was utilized to identify a MKK3 domain responsible for MYC binding. First, an MKK3 model was generated based on the crystal structure of its closest homolog MKK6 (Figure 4a, Supplementary Figure S3 ). The correct tertiary structure of MKK3 was validated through computational docking of adenosine triphosphate, which bound to the MKK3 model with an identical binding mode as has been reported for other MAP kinases ( Figure 4b ). In particular, the adenosine triphosphate phosphate groups were involved in interactions with conserved Lys93 and Lys192 residues, whereas the adenine ring was located in the kinase hinge region, namely in proximity to Glu141 and Met143.
To predict a putative interface surface for the MKK3-MYC interaction, protein-protein docking was performed using the MKK3 model and the available crystal structure of MYC bHLH-LZ domain (PDB ID: 1NKP). 12 Interestingly, the most energetically favorable complex showed the MYC bHLH-LZ domain fitting within a cavity in a small lobe of MKK3 formed by MKK3 residues 101-160. Computational mutation analysis of MKK3 further indicated that the 121-135 region may be important for MYC binding. Results from a computational alanine scanning experiment predict MKK3 residues Phe121, Leu130 and Phe131 may result in significantly decreased binding affinity of MKK3 to MYC with only minor effects on overall MKK3 stability ( Figure 4d ).
The results of computational modeling were utilized to guide experimental determination of MKK3 MYC-binding motif (MBM) ( Figure 5a ). First, MKK3 truncation constructs containing the N-terminal (NTD, residues 1-210) and C-terminal (CT, residues 201-347) fragments of MKK3 were generated (Figures 5a and b) . Using a TR-FRET assay, we observed the interaction between fulllength MYC and the NTD fragment of MKK3 ( Figure 5c ). Then, several smaller fragments of MKK3 NTD were generated and tested, which include MKK3-1-60, 51-110, 101-160 and 101-210. Significant TR-FRET signals were detected for the MYC interaction with full-length, 1-210, 101-210 and 101-160 MKK3 (Figure 5c ). The smallest overlapping region giving a positive signal was a 60residue fragment of MKK3, fragment 101-160, which appears to serve as the main binding site for MYC ( Figure 5b ).
From analysis of the structural model, we identified several structural elements in the MKK3 101-160 fragment (Figure 5a ), including helix C (Ser101-Met115), beta-sheet 4 (Phe121-Asp135), beta-sheet 5 (Asp135-Met140) and helix D (Ser146-Asn158). In order to narrow down the MBM, short MKK3 peptides within the 101-160 fragment were designed and generated, including a helical peptide 101-115, its longer version 101-121, 101-135 that includes helix C and beta-sheet, and 121-135 corresponding to beta-sheet 4 ( Figure 5a ). The fragments of MKK3 were coexpressed as Venus-Flag-tagged fusions with GST-tagged MYC in HEK293T cells and subjected to a GST-pull down assay along with negative controls. A significant band for binding of MYC to MKK3 101-135 and 121-135 peptides was observed compared with the 101-115 and 101-121 fragments, indicating a critical role for MKK3 residues 121-135 in mediating its interaction with MYC ( Figures 5d and e ). Furthermore, we observed selective binding of (Figure 5a ) was identified as a binding site for MYC. This 15-residue region of MKK3 is defined as a MYC-binding motif, or MKK3 MBM and was in excellent agreement with the molecular modeling studies shown in Figure 4 . This site is distinct from those previously described as interaction domains with upstream or downstream MAP kinases, ASK1 and p38, representing a new structural element in MKK3 for signaling relay.
MKK3 stabilizes MYC and enhances MYC-driven transcription
The data from the above structural analysis further support the interaction between residues 121-135 of MKK3 and the MYC bHLH-LZ domain. Next, we sought to understand if MKK3 binding modulates MYC activity. MYC generally has a short half life in cells that, in part, dictates its function. 19 Therefore, the impact of MKK3 expression on MYC protein stability was monitored. 20, 21 Colon cancer HCT116 cells with relatively high expression levels of endogenous MYC 22, 23 were used to monitor MYC protein levels. Although MYC protein was rapidly degraded upon treatment of cells with cycloheximide, it was significantly stabilized in the presence of MKK3, MKK3 121-135 and extracellular signalregulated kinase (ERK1) overexpression (Figure 6a ). Overexpression of Venus had no effect on MYC protein stability. Increased MYC stability in the presence of overexpressed MKK3 was not specific to HCT116 cells, similar effect was observed in MCF7 breast cancer cells (Supplementary Figure S4A) .
To determine the effect of MKK3 on MYC transcriptional activity, a luciferase-based MYC transcriptional reporter assay was performed in HEK293T, HCT116 and MCF7 cells. 24, 25 Cells were transfected with expression vectors for Venus-MKK3, Venus-MKK3 121-135, Venus-ERK1 (positive control) or Venus alone (negative control) in the presence of a MYC E-box-containing luciferase reporter ( Figure 6b ). As expected, 13 overexpressed ERK1 increased MYC-driven transcriptional activity compared with endogenous MYC activity detected with the Venus vector alone. Moreover, overexpression of MKK3 also resulted in increased luminescence of MYC-generated luciferase (Figure 6b, Supplementary Figure S4B ). Interestingly, overexpression of the artificial MKK3 MBM fragment also increased MYC activity compared with the Venus control ( Figure 6b ).
MYC is known to stimulate cell proliferation through upregulation of cyclins and cyclin dependent kinases (for example, CDK4) and suppression of CDK inhibitors such as CDKN1B, CDKN2B or CDKN2A. 26 To determine the effect of MKK3-induced MYC activation on the level of MYC-regulated cell cycle proteins, HCT116 cell lysates expressing MKK3, MKK3 121-135 fragment or Venus vector were analyzed by western blotting. Overexpression of MKK3 full-length and its MBM correlated with increased levels of CCND2 and CDK4 compared with their level in cells expressing Venus alone control (Figure 6c ). Overexpression of MKK3 and MKK3 121-135 consistently led to decreased levels of CDKN1B, confirming MKK3-induced activation of MYC. To further examine the role of MKK3 in the regulation of MYC-induced genes, quantitative reverse-transcriptase PCR was used to monitor the expression level of well-established MYC-driven genes, CDK6 and CDKN2A. Like ERK1, overexpressed MKK3, or MKK3 121-135, increased CDK6 and decreased CDKN2A mRNA levels (Figure 6d ).
Together, our results suggest a novel role for MKK3 as a positive regulator of MYC activity through direct PPI.
DISCUSSION
Here, we presented data supporting the interaction of MKK3 with multiple signaling pathway regulators in addition to its known regulators in the stress activated mitogen-activated protein kinase pathway, ASK1 and p38. These MKK3 partners include CDK4, aurora kinase A, hypoxia-inducible factor 1-beta, Ser/Thr kinase 11, RASSF1, Beclin 1 and MYC. Although the significance of MKK3 interaction with these proteins remains to be established, our results imply that MKK3 may have a broader role as a signaling hub than previously recognized. Indeed, our analysis of ME of genomic alterations provides additional support for a functional connection between MKK3 and its novel protein partners, including MYC, in different types of tumors.
MYC is an oncogenic transcription factor that regulates cell growth and proliferation, and its amplification is correlated with poor survival and prognosis of cancer patients. 27 MYC has been shown to be regulated by a variety of proteins, including other kinases such as ERKs and glycogen synthase kinase 3 beta (GSK3β). Our work identifies MKK3 as a new MYC regulator. Interestingly, we did not detect the interaction between MYC and MKK6, a close homolog of MKK3, under the same experimental conditions. These data suggest that MKK3 and MKK6 have different functions in the regulation of MYC in cancer cells.
The results of TR-FRET and BLI assays performed with recombinant purified MKK3 and the C-terminal MYC-HLH-LZ, as well as our co-IP experiments, suggest a direct physical interaction between MKK3 and MYC. Mechanistically, MKK3 appears to regulate MYC by inhibiting MYC degradation and enhancing its transcriptional activity. Consistent with this role, overexpression of MKK3 in HCT116 cells is correlated with the upregulation of MYC-regulated genes, CDK4, CDK6 and CCND2, and suppression of CDK inhibitors CDKN1B and CDKN2A. These data suggest a new role for MKK3 as an activator of MYC that enhances MYC-driven cell proliferation. Indeed, knockdown of MKK3 in multiple cancer cell lines has been correlated with suppression of cell proliferation. 28 The MYC-binding site is located at the N-terminal part of MKK3 outside of the kinase domain, which suggests a kinaseindependent mechanism for the MKK3-MYC interaction. However, the regulatory function of MKK3 in MYC-driven program remains to be established. It remains possible that the kinase activity is required to regulate the MYC-associated transcription complex upon recruitment. 29, 30 MKK3 is activated by MAP3K kinases, such as ASK1 or TAK1, which bind to a MKK3 DVD docking site formed by C-terminal residues 311-344. 31 Upon its activation, the MKK3 N-terminal 17-33 fragment binds to p38 leading to its phosphorylation and activation. 32 Here, we identified a short fragment (121-135; MBM), located in the central region of MKK3 that binds to MYC. This peptide does not show any significant binding to p38 suggesting a new function for MKK3 in regulation of MYC oncogenic activity aside of p38 acitivation. Furthermore, our discovery of nonoverlapping binding domains in the MKK3 protein for MYC and p38 implies that these different functions of MKK3 could potentially be independently targeted with inhibitors for therapeutic discovery.
In summary, our data reveal MKK3 as a major hub of a cancer PPI network and confirm interactions with at least 10 novel binding partners known as key regulators of cell growth, including the master transcriptional regulator MYC. With specific focus on the MKK3-MYC interaction, we demonstrate that MKK3 can upregulate MYC activity in cancer cells. These data strongly support a new mechanism for the control of the MYC-driven program through MKK3.
MATERIALS AND METHODS
Cell culture conditions
All cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Human lung cancer cells H1299 (ATCC CRL-5803) were cultured in Roswell Park Memorial Institute (RPMI) 1640 containing L-glutamine (Corning, Corning, NY, USA, Cat# 10-040) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution (CellGro, Manassas, VA, USA). HEK293T (ATCC CRL-3216), HeLa (ACTT CCL-2), MCF7 (ACTT HTB-22) and HCT116 (ACTT CCL-247) cells (ATCC, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium, with 4.5 g/l glucose, L-glutamine and sodium pyruvate (CellGro, cat # 10-013-CV) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution (CellGro, cat # 30-002-CI). Cells were incubated at 37°C in humidified conditions with 5% CO 2 .
Transfection
For TR-FRET and GST-pull down assays, the cells were transfected using 1 mg/ml polyethylenimine in a ratio of 3 μl to 1 μg DNA. For MYC reporter, MYC stability and quantitative reverse-transcriptase PCR assays cells were transfected with Xtreme-Gene (Roche, Indianapolis, IN, USA, cat # 6366546001) in a ratio of 3 μl to 1 μg DNA following the manufacturer´s instructions.
Time-resolved fluorescence resonance energy transfer
Test proteins were expressed for 48 h in HEK293T cells. Cell lysates were prepared in the 1% NP-40 lysis buffer (150 mM NaCl, 10 mM HEPES pH 7.5, 1% nonident P-40 (IGEPAL CA-630, Sigma-Aldrich, St Louis, MO, USA), 5 mM sodium pyrophosphate, 5 mM NaF, 2 mM sodium orthovanadate, 10 mg/l aprotinin, 10 mg/l leupeptin and 1 mM phenylmethylsulfonyl fluoride) for 30 min at 4°C, followed by 15 min centrifugation at 14 000 r.p.m. at 4°C. The TR-FRET assay was performed in the reaction buffer (20 mM Tris-HCl pH 7.0, 50 mM NaCl, 0.01% NP-40) in 384-well black plates. GST-Terbiumconjugated antibody (Cisbio Bioassays, Codolet, France; 61GSTTLB, 1:1000 dilution) was used to couple GST-tagged protein as a FRET donor. Venustagged proteins served as a FRET acceptor.
For the TR-FRET assay with recombinant proteins, 6 nM recombinant GST-MKK3 protein was mixed with 50 nM recombinant His-MYC-bHLH-LZ protein in the reaction buffer and the reactions were carried out as described above. Samples were incubated at room temperature for 1 h in 384-well plate, and the FRET signal was measured on the Envision spectrophotometer (Perken Elmer, Waltham, MA, USA) with the following settings: setting: Ex 337 nm, Em1: 520 nm, Em2: 486 nm; mirror: D400/ D505 dual; time delay: 50 μs). The TR-FRET signal is expressed as the FRET ratio (520 nm /486 nm × 10 4 ).
BLI assay
Binding studies were carried out using the Octet Red 384 system (Forte Bio, Fremont, CA, USA), at 30°C with shaking at 1500 r.p.m. in a 384-well plate containing 50 μl of the solution in each well. In all, 1X BLI Kinetic Buffer (phosphate-buffered saline, pH 7.4, 10 mg/ml bovine serum albumin and 0.1% (v/v) Tween 20) was used throughout this study for protein dilution and washing steps. Ni-NTA biosensors were balanced for the first baseline and then loaded with poly-histidine tagged MYC peptide (50 μg/ ml) followed by another wash for the second baseline. Kinetic analysis of the MYC-MKK3 interaction was performed by dipping the sensors into the well containing GST-MKK3 (0-300 nM). The maximum change in light interference in the association step was determined for each GST-MKK3 concentration (using the second baseline value), and a standard curve was plotted using one-site binding (hyperbola) nonlinear regression.
GST-pull down, co-IP and western blot analysis
The GST-pull down and co-IP assays were performed as previously described. 4 For the GST-pull down assays, cells were lysed in the 1% NP-40 Lysis buffer and incubated with glutathione-conjugated beads (GE 17527901) for 2 h at 4°C. Beads were washed three times with the 1% NP-40 lysis buffer and eluted by boiling in sodium dodecyl sulfatepolyacrylamide gel electrophoresis loading buffer. For co-IP, cells were lysed with 0.5% NP-40 lysis buffer as previous described to extract both, cytoplasmic and nuclear proteins, including MYC. 33 Cell lysates were collected and cleared by centrifugation at 14 000 r.p.m. at 4°C for 10 min. The cleared lysates (1.5-2 mg of total proteins) were mixed with protein G-beads (20 μl) for 1 h to remove nonspecific binding proteins. Then, the cleared supernatants were transferred to clean tubes, mixed with MKK3 antibody (10 μg; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, sc135985), or MYC antibody (4 μg Abcam, Cambridge, MA, USA, ab17355) or IgG control (Santa Cruz Biotechnology Inc., sc-2025), and incubated at 4°C overnight. Next day, the samples were incubated with protein G-beads (20 μl) for 2 h at 4°C. Iimmunoprecipitates were washed three times with 500 μl of the lysis buffer. The immunocomplexes were eluted with sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer and analyzed by western blotting with indicated antibodies.
Antibodies
The following antibodies were used for the western blotting: MYC (Cell Signaling, Danvers, MA, USA, 5605S, 1:1000 dilution), γ-tubulin (Sigma-Aldrich, T-5326, 1:2000 dilution), Flag-HRP (Sigma-Aldrich, A8592, 1:1000 dilution), GST-HRP (Sigma-Aldrich, A7340, 1:1000 dilution), MKK3 (Santa Cruz Biotechnology Inc., sc-961, 1:1000 dilution), MYC (Cell Signaling 5605S, 1:1000 dilution), GAPDH (Cell Signaling 2118, 1:1000 dilution), CDKN1B (p27, Cell Signaling 2552, 1:1000 dilution), CCND2 (Cell Signaling 3741P, 1:1000 dilution) and CDK4 (Santa Cruz Biotechnology Inc., sc-260, 1:1000 dilution).
PCA and cell imaging
The cells were co-transfected with MKK3 and MYC or p38 conjugated to C-terminal or N-terminal fragments of Venus. The cells transfected with individual plasmids served as a control. Proteins were expressed for 48 h, and the PPIs were monitored in live cells based on the fluorescence intensity of reconstituted Venus. The cell nuclei were stained with the Hoechst 33342 5 μg/ml solution (Thermo Fisher Scientific Inc., Rockford, IL, USA, cat # H3570) for 30 min at 4°C. The cell images were taken with ImageXpress system (Molecular Devices, Sunnyvale, CA, USA) at 447 nm (Hoechst nuclei stain) and 530 nm (Venus green fluorescence). The fluorescence intensity of reconstituted Venus was measured on the Envision spectrophotometer (Ex 485 nM and Em 535 nm, mirror 505 nm).
Protein stability assay
The proteins were expressed for 24 h and then serum starved for an additional 24 h. Then, cells were treated with 100 μg/ml cycloheximide (Cell Signaling, cat# 2112). At the indicated times, 100 μl of 2X sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer was added and the cells were scraped from the wells, and boiled for 5 min. After all lysates were collected, each sample was loaded onto a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and then analyzed by western blotting.
MYC reporter assay
The MYC transcription activity was measured using MYC reporter assay. 34 Cells were transfected with Venus-Flag-MKK3, Venus-Flag-MKK3 121-135, Venus-Flag-ERK1 or Flag-Venus vector along with Myc-E-box-containing Firefly luciferase reporter plasmid. Renilla luciferase expression vector served as a calibration control. For the dose-dependent assay, MCF7 cells were co-transfected with Venus-Flag-MKK3 or Flag-Venus vector at the final concentration of 0-0.75 ng/μl The proteins were expressed in cells for 24 h in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum, and then serum starved for 24 h. Then, cells were harvested, and transferred to a 384-well plate (20 μl per well). MYC reporter assay was performed using Dual-Glo lucefarase kit (Promega, Madison, WI, USA, cat # E2920) following the manufacturer's instructions. The normalized luminescence was calculated as a ratio of luminescence of Firefly luciferase to the luminescence of Renilla luciferase.
Reverse-transcriptase polymerase chain reaction (qRT-PCR)
HCT116 cells transfected with Venus or Venus-tagged MKK3, MKK3 121-135, or ERK1 were incubated for 24 h in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum, and then serum starved for an additional 24 h. The mRNA was purified using the RNeasy Mini kit (Qiagen, Germantown, MD, USA, cat # 74104) following the manufacturer's instructions. Then, to degrade DNA, the mRNA samples were treated with DNase I (Invitrogen, Carlsbad, CA, USA, cat # 18068015) followed by heat inactivation at 65°C for 10 min in the presence of 2 mM EDTA. Complementary DNA was synthesized using 250 ng of total RNA and the SuperScript IV first-strand cDNA synthesis kit (Invitrogen, cat # 18091050). The real-time PCR was performed using SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad, Hercules, CA, USA, cat #, 172-5271). The delta cycle threshold (ΔCt) values were calculated by subtraction of GAPDH Ct from test gene Ct. Then, relative mRNA levels were calculated by subtraction of Venus ΔCt values from test gene ΔCt values resulting in ΔΔCt value, and the fold change was determined as FC = 2 -ΔΔCt . 35 The primer sequences and the PCR cycling program are indicated in SI.
DNA plasmids and protein purification
The detailed information is provided in Supplementary Information.
MKK3 homology modeling and protein-protein docking
The computational modeling was performed using the Schrodinger Suite software (Schrodinger, Cambridge, MA, USA) as described in Supplementary Information.
Analysis of ME
A ME analysis of genomic alterations of MKK3 and its binding partners was performed with the cBioPortal 36 using TCGA Provisional data sets with sequencing and copy number alteration data from 11 tumor types ( Supplementary Table S1 ).
Data analysis
The TR-FRET, BLI, PCA and quantitative reverse-transcriptase PCR assays were performed and repeated three times. The data quantification was performed using the GraphPad Prism software. (GraphPad Software, Inc., La Jolla, CA, USA)
